TY - JOUR AU - Davis, Jennifer S. AU - Kanikarla-Marie, Preeti AU - Gagea, Mihai AU - Yu, Patrick L. AU - Fang, Dexing AU - Sebastian, Manu AU - Yang, Peiying AU - Hawk, Ernest AU - Dashwood, Roderick AU - Lichtenberger, Lenard M. AU - Menter, David AU - Kopetz, Scott PY - 2020 DA - 2020/09/10 TI - Sulindac plus a phospholipid is effective for polyp reduction and safer than sulindac alone in a mouse model of colorectal cancer development JO - BMC Cancer SP - 871 VL - 20 IS - 1 AB - Non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin and sulindac are effective for colorectal cancer prevention in humans and some animal models, but concerns over gastro-intestinal (GI) ulceration and bleeding limit their potential for chemopreventive use in broader populations. Recently, the combination of aspirin with a phospholipid, packaged as PL-ASA, was shown to reduce GI toxicity in a small clinical trial. However, these studies were done for relatively short periods of time. Since prolonged, regular use is needed for chemopreventive benefit, it is important to know whether GI safety is maintained over longer use periods and whether cancer prevention efficacy is preserved when an NSAID is combined with a phospholipid. SN - 1471-2407 UR - https://doi.org/10.1186/s12885-020-07311-4 DO - 10.1186/s12885-020-07311-4 ID - Davis2020 ER -